Suppr超能文献

体外光化学疗法成功治疗蕈样肉芽肿综合征——印度的首次尝试。

Successful treatment of Sezary syndrome with extracorporeal photopheresis - The first attempt in India.

作者信息

Tiwari Aseem K, Arora Dinesh, Dhiman Pratibha, Kapoor Sheilly, Aggarwal Geet, Dara Ravi C, Vaid Ashok

机构信息

Department of Transfusion Medicine, Medanta-The Medicity, Gurgaon, Haryana, India.

Department of Heamto-oncology, Medanta-The Medicity, Gurgaon, Haryana, India.

出版信息

Asian J Transfus Sci. 2019 Jan-Jun;13(1):66-69. doi: 10.4103/ajts.AJTS_111_18.

Abstract

Sezary syndrome (SS) is more aggressive leukemic variant of cutaneous T-cell lymphoma in which a significant number of circulating malignant (Sezary) cells are observed in peripheral blood. Although single-agent or combination chemotherapy regimens have produced moderately high response rates in patients with advanced-stage SS, these responses are invariably not durable. Extracorporeal photopheresis (ECP) is recommended as an immunomodulator treatment, offering better life quality for patient. We would like to present the first SS case treated successfully with low-dose methotrexate and ECP in India. A 50-year-old male presented with rash and severe pruritus all over the body for 2 years. He had received various treatment regimens but without any symptomatic improvement. He underwent detailed examination and diagnosis of SS was established. Peripheral smear revealed total leukocyte count of 14900/μl with 55% cells reported as Sezary cells. Contrast-enhanced computerized tomography revealed few insignificant (<1.5 cm) bilateral nodes in the axillary and inguinal region. The patient's disease stage was determined IVA1, and grade was T4N0M0B2. He received six cycles of CHOP, which led to a short-term remission of <3 months, and he was started on single-agent methotrexate along with skin supportive treatment. He did not respond to low-dose methotrexate alone, and therefore, ECP was added to treatment regimen. This was possibly the first such treatment for SS patient in India. The patient had very good response after six cycles of ECP with pruritus and itching diminishing and scaly lesions down to <10% of body surface area. There was regrowth of hair all over affected area. Sezary cell counts also came down to 35%. The patient continues to do well post-ECP, with single-agent gemcitabine. ECP either as monotherapy or in combination with other immunotherapies offers a good treatment option to otherwise resistant cases of SS.

摘要

覃样肉芽肿综合征(SS)是皮肤T细胞淋巴瘤中侵袭性更强的白血病变体,在外周血中可观察到大量循环恶性(覃样)细胞。尽管单药或联合化疗方案在晚期SS患者中产生了中等较高的缓解率,但这些缓解往往不持久。体外光化学疗法(ECP)被推荐作为一种免疫调节治疗方法,能为患者提供更好的生活质量。我们想介绍印度首例用低剂量甲氨蝶呤和ECP成功治疗的SS病例。一名50岁男性,全身皮疹和严重瘙痒2年。他接受了各种治疗方案,但症状没有任何改善。他接受了详细检查,确诊为SS。外周血涂片显示白细胞总数为14900/μl,其中55%的细胞被报告为覃样细胞。增强计算机断层扫描显示腋窝和腹股沟区域有少数无意义的(<1.5 cm)双侧淋巴结。患者的疾病分期为IVA1期,分级为T4N0M0B2。他接受了六个周期的CHOP方案治疗,导致短期缓解不足3个月,随后开始使用单药甲氨蝶呤并辅以皮肤支持治疗。他对低剂量甲氨蝶呤单药治疗无反应,因此在治疗方案中加入了ECP。这可能是印度首例针对SS患者的此类治疗。该患者在接受六个周期的ECP治疗后反应良好,瘙痒减轻,鳞屑性皮损面积降至体表面积的<10%。受累区域毛发全部重新生长。覃样细胞计数也降至35%。该患者在接受ECP治疗后继续使用单药吉西他滨,情况良好。ECP无论是作为单一疗法还是与其他免疫疗法联合使用,都为原本耐药的SS病例提供了一个很好的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8887/6580835/b7434f4b2e3b/AJTS-13-66-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验